Nutriband (NASDAQ: NTRB), a company primarily engaged in the development of transdermal pharmaceutical products, announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to strengthen intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology’s abuse-deterrent properties. If granted, the patent could extend protection for AVERSA™-based products, including AVERSA™ FENTANYL, through 2046.
Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulants. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating the AVERSA™ technology, which can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The filing of this patent application is a significant step for Nutriband as it seeks to bolster its intellectual property portfolio and extend the market exclusivity of its abuse-deterrent technology. By potentially securing protection through 2046, the company aims to maintain a competitive edge in the development of safer transdermal pharmaceutical products. For more details, the full press release can be viewed at https://ibn.fm/Osmxh. Additional information about Nutriband is available on its website at www.nutriband.com, and the latest news and updates relating to NTRB can be found in the company’s newsroom at https://ibn.fm/NTRB.
MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, distributed the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
For more information about MissionIR, visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
